Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact on +44 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Zenopa was great at assessing my interests, providing relevant and interesting alternatives for employment opportunities.
Eve, 2014

Orion and Endo Pharmaceuticals to ally on oncology research

28 January 2011 00:00 in Pharmaceutical Company Product News

Orion is entering into partnership with Endo Pharmaceuticals to conduct research into new cancer treatments.

The novel research and development collaboration will pertain to the discovery and commercialisation of eight oncology candidate drugs, with the two firms set to share all associated costs.

Endo will hold the rights to sell the treatments in the US while Orion handles European distribution, with royalties being paid by both companies based on sales performance in their respective territories.

Concurrent to this agreement, Endo has also exercised its option to license the collaboration's lead asset - a treatment for prostate cancer - from Orion, with phase I testing set to begin soon.

Dr Reijo Salonen, senior vice-president of Orion's research and development unit, said: "The agreement is also perfectly in line with Orion's research and development strategy to focus on risk-sharing partnerships."

According to Orion's latest financial report in October 2010, the firm's sales in the first nine months of last year increased by ten percent compared to 2009, with full-year financial data set to be published next month.ADNFCR-8000103-ID-800370821-ADNFCR

Other news stories from 28/01/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2014 Zenopa Ltd